The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 17, 2012
Filed:
Oct. 21, 2010
Ralph Biemans, Rixensart, BE;
Philippe Denoel, Rixensart, BE;
Christiane Feron, Rixensart, BE;
Carine Goraj, Rixensart, BE;
Jan Poolman, Rixensart, BE;
Vincent Weynants, Rixensart, BE;
Ralph Biemans, Rixensart, BE;
Philippe Denoel, Rixensart, BE;
Christiane Feron, Rixensart, BE;
Carine Goraj, Rixensart, BE;
Jan Poolman, Rixensart, BE;
Vincent Weynants, Rixensart, BE;
GlaxoSmithKline Biologicals s.a., Rixensart, BE;
Abstract
The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtBis shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS invaccine compositions. Bleb vaccines derived from lgtBand capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.